How much funding has Obsidian Therapeutics raised?

Obsidian Therapeutics has raised $325.0M in total funding, most recently a Series C round.

Who are Obsidian Therapeutics's investors?

Obsidian Therapeutics's investors include Wellington Management, GV, Atlas Venture, Bristol Myers Squibb, Vertex Ventures HC, Amgen.

When was Obsidian Therapeutics founded?

Obsidian Therapeutics was founded in 2015.

Where is Obsidian Therapeutics headquartered?

Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Obsidian Therapeutics in?

Obsidian Therapeutics operates in Biotech.

How many employees does Obsidian Therapeutics have?

Obsidian Therapeutics has 51-200 employees.

Obsidian Therapeutics

The next generation of engineered therapeutics

Cambridge, United States · Founded 2015 · $325.0M raised

Biotech

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2015
Business Model: B2B

Website: obsidiantx.com
Total Funding: $325.0M
Last Round: $160.5M Series CApr 2024
Rounds: 3

About

Obsidian Therapeutics is a clinical-stage biopharmaceutical company pioneering engineered cell and gene therapies using its proprietary cytoDRiVE platform, which enables precise, patient-specific control of therapeutic proteins. The company's TIL and adoptive cell therapy programs for cancer have scientific roots in Stanford University's Wandless Lab.

Summary

Obsidian Therapeutics is a Biotech company based in Cambridge, United States, founded in 2015. It has raised $325.0M in total across 3 rounds, most recently a $160.5M Series C round in Apr 2024. Investors include Wellington Management, GV and Atlas Venture.

LinkedIn X (Twitter)